Technical Analysis for BCYC - Bicycle Therapeutics plc

Grade Last Price % Change Price Change
grade F 8.615 5.84% 0.48
BCYC closed up 5.84 percent on Wednesday, November 13, 2019, on 16 percent of normal volume. The stock exhibited some range contraction during this trading session as price made an NR7 -- narrowest range of the last seven sessions. Note that the stock is in oversold territory based on its Slow Stochastic indicator (14, 3, 3) -- sideways movement or a bounce should not be unexpected.

Trend Table & Recent Signals
ADX Long-Term Intermediate-Term Short-Term
Weak or Absent N/A Down Down
See historical BCYC trend table...

Date Alert Name Type % Chg
Non-ADX 1,2,3,4 Bearish Bearish Swing Setup 0.00%
Stochastic Buy Signal Bullish 0.00%
NR7 Range Contraction 0.00%
Inside Day Range Contraction 0.00%
Oversold Stochastic Weakness 0.00%
Non-ADX 1,2,3,4 Bearish Bearish Swing Setup 5.84%
Lower Bollinger Band Walk Weakness 5.84%
Inside Day Range Contraction 5.84%
Oversold Stochastic Weakness 5.84%
Non-ADX 1,2,3,4 Bearish Bearish Swing Setup 6.23%

Older signals for BCYC ...

Get a Trading Sidekick!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:
Profile
Bicycle Therapeutics Limited, a clinical-stage biopharmaceutical company, develops a class of medicines for diseases that are underserved by existing therapeutics. Its lead product candidate is BT1718, a bicycle toxin conjugate (BTC), which is in Phase I/IIa clinical trials targeting tumors that express Membrane Type 1 matrix metalloprotease. The company's oncology product candidates also comprise BT5528, a BTC that is in preclinical studies targeting EphA2; BT8009, which is in preclinical studies targeting Nectin-4; and CD137, an immune cell co-stimulatory molecule that is in preclinical stage, as well as systemically-delivered activators. In addition, it is developing THR-149, a key immune cell co-stimulatory molecule that is in Phase I clinical trials. Further, the company collaborates with biopharmaceutical companies and organizations to develop programs in therapeutic areas, such as anti-infective, cardiovascular, hematology, ophthalmology, and respiratory indications. The company has a clinical trial and license agreement with the Cancer Research Technology Limited and CRUK; and research collaboration agreement with Bioverativ Inc., AstraZeneca AB, and Oxurion NV. The company was incorporated in 2009 and is headquartered in Cambridge, the United Kingdom.
Medicine Biopharmaceutical Health Life Sciences Diseases Immunology Oncology Tumors Astrazeneca Immune Checkpoint
Is BCYC a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 0 bullish, 2 bearish and 3 neutral indicators. You may wish to incorporate that into your trading strategies.
Indicators
Indicator Value
52 Week High 14.91
52 Week Low 6.2401
Average Volume 22,192
200-Day Moving Average 0.0
50-Day Moving Average 9.649
20-Day Moving Average 9.1075
10-Day Moving Average 8.713
Average True Range 0.743
ADX 21.37
+DI 8.6434
-DI 18.6655
Chandelier Exit (Long, 3 ATRs ) 8.251
Chandelier Exit (Short, 3 ATRs ) 10.329
Upper Bollinger Band 10.2122
Lower Bollinger Band 8.0028
Percent B (%b) 0.28
BandWidth 24.259127
MACD Line -0.3805
MACD Signal Line -0.2849
MACD Histogram -0.0956
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 9.31
Resistance 3 (R3) 9.24 8.93 9.20
Resistance 2 (R2) 8.93 8.75 8.96 9.16
Resistance 1 (R1) 8.77 8.64 8.85 8.85 9.12
Pivot Point 8.46 8.46 8.50 8.50 8.46
Support 1 (S1) 8.31 8.28 8.38 8.38 8.11
Support 2 (S2) 8.00 8.17 8.03 8.07
Support 3 (S3) 7.84 8.00 8.03
Support 4 (S4) 7.92